Wound infection · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes wound infection compared with passive drain following pancreatic surgery (very low certainty).
1 finding from 1 review
Drain‐related complications · people undergoing elective pancreatic resections
1 finding from 1 review
Morbidity · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes morbidity compared with passive drain following pancreatic surgery (very low certainty).
1 finding from 1 review
Length of hospital stay · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes length of hospital stay compared with passive drain following pancreatic surgery (very low certainty).
1 finding from 1 review
All‐cause mortality · people undergoing elective pancreatic resections
It is very uncertain whether active drain changes mortality compared with passive drain following pancreatic surgery (very low certainty).
2 findings from 1 review
Number of responders · IBD patients
IV iron sucrose showed no clear difference in number of responders ‐ active or inactive disease (6 weeks) compared with oral iron sulphate (low certainty).
1 finding from 1 review
Number of responders · IBD patients
It is very uncertain whether IM erythropoietin changes number of responders ‐ active disease (12 weeks) compared with oral placebo (very low certainty).
1 finding from 1 review
Number of responders · IBD patients
1 finding from 1 review
Serious adverse events ‐ active or inactive disease (14 days) · IBD patients
It is very uncertain whether oral iron sulphate changes serious adverse events ‐ active or inactive disease (14 days) compared with oral iron hydroxide polymaltose complex (very low certainty).
1 finding from 1 review
Intervention not reported
H. pylori eradication therapy versus no active treatment · people with Helicobacter pylori‐positive peptic ulcer
The intervention may leads to lower H. pylori eradication therapy versus no active treatment (low certainty).
1 finding from 1 review
Intervention not reported
H. pylori eradication therapy versus no active treatment · prevention of recurrence in people with Helicobacter pylori‐positive peptic ulcer
It is very uncertain whether the intervention changes H. pylori eradication therapy versus no active treatment (very low certainty).
1 finding from 1 review
Intervention not reported
Colonic transit rate (geometric centre of radioactive substance). Unit indicates position along with intestinal tract. Scale from: 1 (small intestine) to 5 (rectosigmoid area). · children with chronic constipation
1 finding from 1 review
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes clinical relapse (at 22 weeks, CDAI > 150) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes loss of clinical response (at 22 weeks, less than 100 points in CDAI… compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Serious adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical relapse · patients with Crohn's disease (active disease population with clinical response at baseline)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Loss of clinical response (at 22 weeks, less than 100 points in CDAI change) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes loss of clinical response (at 56 weeks, less than 100 points in CDAI… compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Serious adverse events (at 56 weeks) · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes serious adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review